Flamel Technologies SA, of Lyon, France, said the first patient was dosed in its Rest-On phase III trial of FT218, a once-nightly formulation of sodium oxybate using the company's Micropump technology, for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy patients.